Elevated concentrations of lipoprotein(a) are not associated with adverse cardiovascular outcomes among patients with a recent acute coronary syndrome treated with statins, according to a new ...

Please provide your email address to receive an email when new articles are posted on . NEW ORLEANS — Major adverse CV events were predicted in patients with recent ACS based on their lipoprotein(a) ...

Results showed that IRs of MACE and MI per 100 person-years increased corresponding with the patient’s 10-year ASCVD risk score. 2,3 However, a substantially significant increase was seen among those ...

Baseline lipoprotein a, or Lp(a), levels are strongly associated with major adverse cardiovascular events (MACE) in high-risk patients with elevated triglyceride levels receiving statin therapy, a new ...

Please provide your email address to receive an email when new articles are posted on . The risk for major adverse CV events after recent ACS could be predicted by baseline lipoprotein(a) and ...

Patients with PAD who have elevated lipoprotein(a) levels and who undergo peripheral endovascular procedures are at increased risk for adverse CV and limb events in the ensuing years, a Japanese study ...

Marking World Heart Day (September 29), Arnab Roy, Kshama Pimpalgaonkar, Abhik Banerjee, and Faisal Khan, Division of R&D and Department of Biochemistry; (SRL Mumbai) elaborate on the Indian phenotype ...

Many more people are at risk for early cardiovascular events because of raised Lp(a) levels than from having familial hypercholesterolemia (FH), a new study suggests. The Danish study set out to try ...

CARLSBAD, Calif., Aug. 2, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that pelacarsen, formerly known as AKCEA-APO(a)-LRx, and licensed by Novartis (NYSE: NVS) for ...